MCRB | tickerfilter.com

Fundamental analysis

25%

Profitability 0%

Dept financing 40%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.75%

1 Month

-37.59%

3 Months

-46.86%

6 Months

-60.04%

1 Year

1,157.23%

2 Year

840.75%

Key data

Stock price

$9.13

P/E Ratio

31.23

DAY RANGE

$9.05 - $9.51

EPS

$2.34

52 WEEK RANGE

$0.36 - $29.98

52 WEEK CHANGE

$1,157.23

MARKET CAP

168.438 M

YIELD

N/A

SHARES OUTSTANDING

9.047 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-07-2025

BETA

1.98

PUBLIC FLOAT

AVERAGE 10 VOLUME

$42,929

AVERAGE 30 VOLUME

$99,613

Company detail

CEO: Eric D. Shaff
Region: US
Website: serestherapeutics.com
Employees: 330
IPO year: 2015

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Seres Therapeutics, Inc. engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection. SER-155, a cultivated bacteria microbiome drug, is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases.

MCRB - Seres Therapeutics, Inc.